Table 1 Patient characteristics
From: Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
Total N = 570 | CD N = 411 | UC N = 148 | IBDU N = 11 | |
|---|---|---|---|---|
Follow-up | ||||
Length, mean, range | 9.2 yrs (range 0.1–49.1) | 9.5 yrs (range 0.1–49.1) | 8.6 yrs (range 0.2–32.3) | 4.9 yrs (range 0.8–10.5) |
Length, median | 6.9 yrs | 7.0 yrs | 6.9 yrs | 4.8 yrs |
Gender | ||||
Male | 258 (45.3) | 169 (41.1) | 85 (57.4) | 4 (36.4) |
Female | 312 (54.7) | 242 (58.9) | 63 (42.6) | 7 (63.6) |
Age at diagnosis | ||||
Mean, range | 27 yr (range 5–79) | 27 yr (range 5–79) | 28 yr (range 8–69) | 32 yr (range 17–47) |
Median | 25 yr | 25 yr | 26 yr | 32 yr |
Disease location CD | ||||
L1—terminal ileum | 99 (24.1) | |||
L2—colon | 90 (21.9) | |||
L3—ileocolon | 120 (29.2) | |||
(+) L4—upper GI tract | 63 (15.3) | |||
Other | 0 (0) | |||
Unknown | 21 (5.1) | |||
No inflammation | 18 (4.4) | |||
Disease location UC | ||||
E1—proctitis | 8 (5.0) | 7 (4.7) | 1 (9.1) | |
E2—left sided colitis | 69 (43.4) | 64 (43.2) | 5 (45.4) | |
E3—pancolitis | 73 (45.9) | 69 (46.6) | 4 (36.4) | |
No inflammation | 3 (1.9) | 3 (2.0) | 0 (0) | |
Other | 2 (1.3) | 1 (0.7) | 1 (9.1) | |
Unknown | 4 (2.5) | 4 (2.7) | 0 | |
Backwash ileitis | 35 | 22 | 3 | |
Rectal sparing | 19 | 16 | 1 | |
Disease behaviour CD | ||||
B1—luminal disease | 126 (30.7) | |||
B2—stenosis | 89 (21.7) | |||
B3—abscesses and/or fistula | 181 (44.0) | |||
P—perianal disease | 144 (35.0) | |||
Unknown | 15 (3.6) | |||
Extra-intestinal | 172 (30.2) | 134 (32.6) | 36 (24.3) | 2 (18.2) |
Family history of IBD | ||||
Yes | 127 (22.3) | 98 (23.8) | 25 (16.9) | 4 (36.4) |
No | 380 (66.7) | 267 (65.0) | 108 (73.0) | 5 (45.4) |
Not documented | 63 (11.0) | 46 (11.2) | 15 (10.1) | 2 (18.2) |
Family history of CRC | ||||
Yes | 36 (6.3) | 22 (5.4) | 13 (8.8) | 1 (9.1) |
No | 469 (82.3) | 342 (83.2) | 119 (80.4) | 8 (72.7) |
Not documented | 65 (11.4) | 47 (11.4) | 16 (10.8) | 2 (18.2) |